Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma

Background and Aims This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti‐platelet agents or anticoagulants. Methods Patients were divided into those using (IM out) and those not using (IM in) anti‐platelet age...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver international 2024-08, Vol.44 (8), p.1751-1761
Hauptverfasser:	Moriguchi, Michihisa, Okuda, Keiichiro, Horiguchi, Go, Kataoka, Seita, Seko, Yuya, Yamaguchi, Kanji, Nishimura, Takeshi, Fujii, Hideki, Mitsumoto, Yasuhide, Miyagawa, Masami, Kirishima, Toshihiko, Okishio, Shinya, Hara, Tasuku, Ishikawa, Hiroki, Nagao, Yasuyuki, Jo, Masayasu, Ishii, Michiaki, Tanaka, Saiyu, Yamauchi, Norihito, Mitsuyoshi, Hironori, Nakajima, Tomoki, Taketani, Hiroyoshi, Yano, Kota, Arai, Masahiro, Umemura, Atsushi, Itoh, Yoshito
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events anticoagulant therapy Anticoagulants anti‐platelet therapy atezolizumab + bevacizumab Bevacizumab Effectiveness Hemorrhage Hepatocellular carcinoma Liver cancer Multivariate analysis Platelets Portal vein Safety Survival Therapy Thromboembolism Thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!